Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10- Capsules Each (30 ...
FDA Drug Recall #D-0321-2020 — Class III — October 16, 2019
Recall Summary
| Recall Number | D-0321-2020 |
| Classification | Class III — Low risk |
| Date Initiated | October 16, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Amneal Pharmaceuticals, Inc. |
| Location | Brookhaven, NY |
| Product Type | Drugs |
| Quantity | 2460 cartons/3 blister cards/10 capsules each |
Product Description
Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10- Capsules Each (30 Capsules)-. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC 69238-1174-3
Reason for Recall
Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits.
Distribution Pattern
Recalled product was distributed to retailers and wholesalers who may have further distribute the product.
Lot / Code Information
Batch Numbers: BL10917, BL11017, BL11117, Exp. date 11/2019
Other Recalls from Amneal Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0613-2020 | Class II | Ranitidine Tablets, USP 300 mg - a).30-count bo... | Nov 22, 2019 |
| D-0616-2020 | Class II | Ranitidine Tablets, USP 300 mg, 250-count bottl... | Nov 22, 2019 |
| D-0612-2020 | Class II | Ranitidine Tablets, USP 150 mg a).60-count bot... | Nov 22, 2019 |
| D-0615-2020 | Class II | Ranitidine Tablets, USP 150 mg, 1000-count bott... | Nov 22, 2019 |
| D-0614-2020 | Class II | Ranitidine Syrup Oral Solution 15 mg/mL 6. fl. ... | Nov 22, 2019 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.